// App-Quantinova.ai

2998 : Elotuzumab can costimulate NK cell responses by engaging SLAMF7

Researchers

Presenter

  • Tatiana Pazina

Principal Investigators

  • Ashley Mentlik James

  • Alexander W. MacFarlane

  • Natalie A. Bezman

  • Robert F. Graziano

  • Michael D. Robbins

  • Adam D. Cohen

  • Kerry S. Campbell

Medical Centers

  • Fox Chase Cancer Center, Philadelphia, PA

  • Bristol-Myers Sqiubb, Princeton, NJ

  • University of Pennsylvania, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Natural Killer cells

  • Cluster of differentiation 69

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Elotuzumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved